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Abstract
Background: C1q represents the initiating protein of the classical complement cascade, however recent findings
indicate pathway independent roles such as developmental pruning of retinal ganglion cell (RGC) axons. Furthermore,
chronic neuroinflammation, including increased expression of C1q and activation of microglia and astrocytes, appears
to be a common finding among many neurodegenerative disease models. Here we compare the effects of a retinal
ischemia/reperfusion (I/R) injury on glial activation and neurodegeneration in wild type (WT) and C1qa-deficient mice
in the retina and superior colliculus (SC). Retinal I/R was induced in mice through elevation of intraocular pressure to
120 mmHg for 60 min followed by reperfusion. Glial cell activation and population changes were assessed using
immunofluorescence. Neuroprotection was determined using histological measurements of retinal layer thickness, RGC
counts, and visual function by flash electroretinography (ERG).
Results: Retinal I/R injury significantly upregulated C1q expression in the retina as early as 72 h and within 7 days in
the superficial SC, and was sustained as long as 28 days. Accompanying increased C1q expression was activation of
microglia and astrocytes as well as a significantly increased glial population density observed in the retina and SC.
Microglial activation and changes in density were completely ablated in C1qa-deficient mice, interestingly however
there was no effect on astrocytes. Furthermore, loss of C1qa significantly rescued I/R-induced loss of RGCs and
protected against retinal layer thinning in comparison to WT mice. ERG assessment revealed early preservation of
b-wave amplitude deficits from retinal I/R injury due to C1qa-deficiency that was lost by day 28.
Conclusions: Our results for the first time demonstrate the spatiotemporal changes in the neuroinflammatory
response following retinal I/R injury at both local and distal sites of injury. In addition, we have shown a role for C1q as
a primary mediator of microglial activation and pathological damage. This suggests developmental mechanisms of C1q
may be re-engaged during injury response, modulation of which may be beneficial for neuroprotection.
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Background
Ischemic events in the CNS cause traumatic tissue dam-
age and irreversible loss of neurons present at the ische-
mic core and surrounding areas. The metabolic demands
of the retina are among the highest of any tissue within
the body, receiving a dual blood supply from both the
choriocapillaris and the central retinal artery (CRA) [1].
Thus, transient retinal ischemic attacks often cause per-
manent tissue damage resulting in irreversible vision loss.
Following ischemic events in the CNS, there is a signifi-
cant and detrimental upregulation of biological factors
including excess ion influx, excitatory neurotransmitter
release, free radical formation, and inflammation [2–4].
Neuroinflammation represents a complex event in the
CNS, often involving an activated cellular response from
resident immune cells. Once activated, these glial cells se-
crete a host of pro-inflammatory proteins propagating a
chronic cascade of apoptotic or phagocytic events [4].
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Two of the primary effector cells during neuroinflam-
mation are the microglia and astrocytes. Both constitute
two of the resident immune cells of visual system (the
retina, optic nerve, and visual centers of the brain). As-
trocytes maintain direct contact with the neurons, blood
vessels, and other glial cells, providing metabolic sup-
port, modulating synaptic activity, and maintenance of
the blood-brain barrier [5, 6]. Microglia represent the
resident myeloid cells of the CNS, derived from primi-
tive macrophages of the yolk sac that colonize the
neuroepithelium prior to the formation of the blood-
brain barrier, separating microglia from circulating mac-
rophages. In addition to their antigen-presenting and
phagocytic capabilities, their processes are constantly in
a mode of surveillance [5, 7–10]. However, when glia are
stimulated by disease or injury, they shift to an activa-
tion state leading to the production of inflammatory me-
diators such as chemokines, cytokines, and complement
proteins [11–13]. Activation of brain astrocytes causes a
dramatic upregulation by at least four-fold of over 260
genes compared to that of quiescent astrocytes, with
some genes showing 10 to 100-fold changes in expres-
sion [14]. Accompanying these changes, reactive astro-
cytes undergo cell proliferation, somatic hypertrophy,
overlapping of processes, and scar formation [15]. Like-
wise, microglia when stimulated undergo a well-defined
morphological transformation, proliferation and migra-
tion, as well as expression of adhesion molecules [16].
These reactive microglia are often observed at sites of
pathology in several neurodegenerative diseases includ-
ing Alzheimer’s disease and glaucoma [17]. Coupled with
their secretion of pro-inflammatory factors such as
TNF-α, IL-1β, and C1q, microglia are an ideal candidate
as a primary mediator of damage.
C1q, the initiating protein of the classical Complement
cascade, is a large complex comprised of six A, six B,
and six C chains. Each chain contains a globular region
at the carboxyl terminus and a collagen-like stem region
at the amino-terminus [18]. Traditionally, the classical
pathway is the antibody-dependent activation of comple-
ment, as C1q is known to bind to the surface of foreign
substances and antibodies [19]. However, recent evi-
dence demonstrates classical complement proteins con-
tribute to various neurodegenerative and age-related
diseases [20]. In the DBA/2 J model of spontaneous
glaucoma, C1qa was among the earliest differentially
regulated genes not only in the retina, but also at the
optic nerve head (ONH) prior to onset of a glaucomat-
ous phenotype [21, 22]. More surprisingly, during devel-
opment in the dorsal lateral geniculate nucleus (dLGN),
C1q colocalized with either immature pre- or post-
synaptic markers, and loss of C1q resulted in retention
of overlapping inappropriate connections [22, 23]. Fur-
thermore, C1q expression in certain areas of the brain
was found to increase more than 300-fold during normal
aging in the mouse. Reduced levels of cognitive and
memory decline were observed in aged C1qa-knockout
mice compared with age-matched WT mice [24].
In this study, we demonstrate the impact of the neu-
roinflammatory response following an ischemic event in
the retina. We identify time dependent increases in cell
density and morphological changes of both astrocytes
and microglia not only in the retina but also the superior
colliculus, a primary termination site of retinal ganglion
cell (RGC) axons exiting the retina. Furthermore, we ob-
served significant increases in C1q expression correlat-
ing with reactive gliosis. Our goal was to determine if
genetic deletion of C1qa could morphologically and
functionally protect the retina from pathological changes
resulting from retinal I/R injury that we have previously
characterized [25], as well as attenuate the activation of
glial cells in the visual system.
Results
C1q expression in the visual axis following I/R injury
Upregulation of complement expression is well docu-
mented following ischemic injury; however, temporal
changes in C1q expression after retinal I/R have not
been identified. In eyes receiving one hour of ischemic
injury, C1q was observed primarily in the inner neural
retina, extending from the nerve fiber layer (NFL) through
the inner plexiform layer (IPL) (Fig. 1a–f ). Quantification
of fluorescence intensity revealed statistically significant
differences (p < 0.01) between ischemic (5.5 × 106 ± 9.6 ×
105) and uninjured eyes (2.4 × 106 ± 3.5 × 105) as early as
day 3, and remaining elevated as long as 28 days (5.3 ×
106 ± 5.1 × 105) (Fig. 1g), with a peak intensity 21 days post
injury. No changes were observed between uninjured eyes
of experimental mice and retinas from naïve mice.
The primary termination site of a majority of RGC
axons in rodents is in the superficial superior colliculus
(SC) of the optic tectum. A significant majority of the
axons have been shown to cross the optic chiasm and
synapse with the hemisphere of the SC contralateral to
the eye from which the axons are projecting [26]. Our
lab has previously identified the specific areas of the
superficial SC innervated by RGC axons using the retro-
grade fluorescent tracer cholera toxin β (CTB 488) [27].
The RGC axons synapse with relay neurons in order to
transfer signals from the retina to the visual cortex. We
investigated if a local injury to the retina caused changes
in C1q expression at these distal sites in the visual axis.
On day 7 the SC hemisphere contralateral to the ische-
mic eye, henceforth labeled the ischemic hemisphere,
displayed a significant elevation in C1q expression in
comparison to the ipsilateral hemisphere receiving input
from the uninjured retina (Fig. 2a). Basal expression of
C1q was also observed in the cortex but appeared to be
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Fig. 1 Retinal I/R injury significantly increases C1q expression in the retina. C57BL/6 J mice were subjected to unilateral I/R injury and sacrificed at
the indicated time points post I/R. Contralateral control eyes (a) displayed basal deposits of C1q in the GCL; however, ischemic eyes (b–f) had
significantly greater expression of C1q as early as day 3 (b) and sustained to the end of the time course on day 28 (f). Positive labeling was only
observed in the GCL and IPL. (g) Fluorescence intensity quantification revealed statistically significant upregulation of C1q (p < 0.01) at all time
points in ischemic versus uninjured retinas. Peak intensity in ischemic eyes was observed on day 21 post injury (p < 0.05). Mean ± SEM, n = 7 per
group. **p < 0.01 determined by student’s paired t-test, #p < 0.05 tested using One-way ANOVA followed by Holm-Sidak post test. GCL = Ganglion
Cell Layer, INL = Inner Nuclear Layer, ONL = Outer Nuclear Layer. Scale bars = 50 μm
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unaffected by retinal I/R. As in the retina, we quantified
differences in C1q expression between the two hemi-
spheres over the 28 day time course. Significant eleva-
tion of C1q expression was observed as early as day 7
between hemispheres corresponding to the ischemic
(1.8 × 107 ± 2.4 × 106) and uninjured (8.5 × 106 ± 1.9 ×
106) eyes. Interestingly by day 14, although not signifi-
cant, an increase in C1q was apparent in the ipsilateral
hemisphere. A second wave of C1q activity was observed
at day 28 post injury, displaying peak intensity in both
hemispheres. Expression of C1q in the contralateral SC
on day 28 was statistically significant (p < 0.05) com-
pared to all earlier time points in (Fig. 2b).
Ischemic induced gliosis in the visual axis
Ischemic attacks in the CNS are known to activate resi-
dent glial cells [4] therefore, we investigated spatiotempo-
ral changes in both microglia and astrocytes (including
Müller cells in the retina) accompanying upregulation of
C1q following retinal I/R injury. As expected, representa-
tive images (Fig. 3a–d) display morphological differences
identified between glial cells of uninjured (Fig. 3a and c)
and ischemic (Fig. 3b and d) retinas. Activation of micro-
glia is commonly identified by a change from a resting
ramified morphology (Fig. 3i) to an amoeboid shape
(Fig. 3ii). Activation of astrocytes and Müller cells is ob-
served by upregulation of GFAP expression, as well as out-
ward extension of their processes from the astrocyte
somas and Müller cell end feet in the GCL (Fig. 3d).
Quantification of these changes based upon percent area
revealed significant differences in Iba1+ retinal microglia
density in ischemic eyes as early as day 3 (1.73 % ± 0.35),
and sustained over the entire 28 day time course (p < 0.01)
compared to contralateral retinas (0.61 % ± 0.13) (Fig. 3e).
While GFAP does not distinguish between astrocytes and
Müller cells, there was an observed increase in GFAP+
cells beginning on day 3; however, a statistically significant
difference between ischemic (3.56 % ± 0.34) and uninjured
eyes (1.74 % ± 0.34) was not seen until day 7 (Fig. 3f). In-
creased density of GFAP+ cells was significantly different
throughout our time course (p < 0.01), displaying a grad-
ual increase as pathology progressed. No significant
changes were observed in any glial cell type between unin-
jured contralateral retinas and those of naïve mice.
Given that the upregulation of C1q in the retina was
accompanied by reactive gliosis, we reasoned a similar
effect would be observed in the SC. Similar to our obser-
vation of retinal C1q expression, there was a marked dif-
ference in glial cell activity in the superficial layers of the
SC, correlating to regions of synaptic termination sites
of RGC axons (Fig. 4a–d). Both astrocytes (Fig. 4b) and
microglia (Fig. 4d) were observed in a reactive morpho-
logical state in the contralateral hemispheres from ische-
mic eyes in comparison to the ipsilateral hemisphere as
early as 7 days post injury. Cell density of both Iba1+
and GFAP+ cells was quantitated in a similar method to
our retinal analysis. A very statistically significant (p <
0.001) difference in microglial density between hemi-
spheres was seen as early as day 7 (2.56 % ± 0.29 com-
pared to 1.27 % ± 0.23). Density of microglia appeared to
drop by day 14, and in a biphasic manner steadily
returned on day 28 to peak levels observed on day 7
(Fig. 4e). No significant differences were observed in
astrocyte population density between contralateral and ip-
silateral hemisphere measurements (Fig. 4f). Interestingly,
Fig. 2 Local ischemic injury in the retina increases expression of C1q
in the SC. (a) Representative images displaying differences in C1q
expression between hemispheres of the SC 7 days following retinal
I/R. Yellow outline indicates area of SC measured, scale = 20×.
(b) Quantification of fluorescence intensity indicated significant
differences between ipsilateral (uninjured) and contralateral
(ischemic) hemispheres on days 7 and 28 (p < 0.01). C1q expression
was greatest on day 28 in both hemispheres of the SC, and
significantly different versus all time points assessed. Mean ± SEM,
n = 7 per time point. **p < 0.01 using student’s paired t-test between
hemispheres within a time point, #p < 0.05 ##p < 0.01 compared
across time points within a group determined via One-way ANOVA
followed by Holm-Sidak post test. Scale bars = 100 μm
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microglia and astrocyte densities in the hemispheres ipsi-
lateral from injured eyes began significantly increasing on
day 21 (p < 0.01) for microglia and day 28 (p < 0.05) for as-
trocytes (Fig. 4e, f ). Whereas previously significant differ-
ences between SC hemispheres could be determined in
Iba1+ populations, by day 21 both hemispheres were indis-
tinguishable. Our quantification reveals concurrent and
progressive increases in C1q expression and glial cell ac-
tivity in both local and distal tissue sites of the visual axis
following retinal I/R.
Fig. 3 Activation and increased cell populations of macroglia and microglia in the retina post I/R. Representative images of Iba1- and GFAP-positive
cells in uninjured (a), (c) and ischemic (b), (d) retinas. a, b Yellow inset boxes of selected Iba1+ microglia demonstrate morphological differences
between senescent (i) and activated (ii) cellular states. c, d Morphological differences observed in GFAP+ cells following ischemia. Astrocytes and Müller
cells display elongated processes extending through the layers of the retina in addition to thickened cell bodies present in the GCL and
NFL. e, f Thresholding analysis based upon percent area of retina occupied was applied to determine changes in cell density. Microglial density
(e) was significantly increased in ischemic retinas at all time points quantified compared with uninjured controls. Density of macroglia (f) trended
upward on day 3 and was statistically significant at all time points measured thereafter. Mean ± SEM, n = 7 per group. *p < 0.05 **p < 0.01 ***p < 0.001
using students paired t-test between control and ischemic groups. GCL = Ganglion Cell Layer, INL = Inner Nuclear Layer, ONL = Outer Nuclear Layer
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C1q mediates morphological damage in the retina
Previously we have published morphological degener-
ation and altered retinal gene expression resulting from
retinal I/R [25]; here we employ several of those same
assays to observe these changes in WT, heterozygous, or
homozygous mice null for C1qa. Retinal I/R caused a
thinning of the inner layers of the neural retina associ-
ated with a loss in the neurons residing in the GCL, IPL,
and INL, the same layers in which we observed a pro-
longed neuroinflammatory response. However, we ob-
served a significant protection of all of these layers in
C1qa+/− and C1qa−/− mice (Fig. 5a). We further quanti-
fied these findings through caliper measurements using
ImageJ. Overall, we found no statistical differences be-
tween the total thicknesses of uninjured retinas (327.6 ±
7.9 μm) compared with the ischemic retinas of C1qa+/−
Fig. 4 Retinal I/R activates and increases glial cell populations in the SC. Representative images demonstrate differences observed in astrocytes
(a), (b) and microglia (c), (d) between uninjured ipsilateral and I/R-receiving contralateral hemispheres of the SC. (e) Quantification of microglial
density was observed to be significantly different between hemispheres on days 7 and 14 (p < 0.01) following I/R. No differences were detected
between hemispheres by 21 days post injury. However, a statistically significant difference was determined in the uninjured ipsilateral hemisphere
when days 21 (p < 0.01) and 28 (p < 0.001) were compared to earlier time points. (f) Density of GFAP+ astrocytes was quantified; however, no
significant differences could be determined between SC hemispheres at any time point following retinal I/R. However, statistical differences
(p < 0.05) were observed in both ipsilateral and contralateral hemispheres when day 28 was compared against astrocyte density on days 14 and
21. Mean ± SEM, n = 7 per group. **p < 0.01 using students paired t-test between ipsilateral and contralateral hemispheres, #p < 0.05 ##p < 0.01
###p < 0.001 across time points determined by One-way ANOVA followed by Holm-Sidak post test. Scale bars = 100μm
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(317.0 ± 10.9 μm) and C1qa−/− (309.5 ± 14.5 μm). Fur-
thermore, a significant difference was quantified in both
the IPL (p < 0.05) and INL (p < 0.001) when comparing
WT and C1qa−/− mice (Fig. 5b). Control measurements
were performed in both naïve and uninjured eyes in
both C1qa mutant genotypes for phenotypic variation,
and no significant differences in individual layer or
total retinal thickness were observed (Additional file 1:
Figure S1A). All measurements were performed under
masked conditions.
In addition to deficits in retinal layer thickness, a sig-
nificant loss of RGCs occurred following I/R injury. Two
independent methods of cell counting were utilized to
assess loss of RGCs between ischemic eyes of our three
genotypes. Representative images demonstrate the dif-
ferences observed in the GCL of H&E stained retinas
between control and ischemic retinas of WT and C1qa-
deficient animals (Fig. 6a). Cell counts revealed a statisti-
cally significant loss (p < 0.01) in ischemic eyes of WT
mice (317 ± 23 cells per mm) in comparison to their
Fig. 5 C1qa-deficiency protects against retinal thinning resulting from ischemic injury. (a) Representative H&E stained retinal cross-section images
demonstrating the differences in retinal morphology observed in animals receiving retinal I/R injury compared with an uninjured retina. Retinas
from WT mice were observed to have significant thinning of the IPL and INL, as well as dramatic loss of the NFL. However, retinas from C1qa+/−
and C1qa−/− showed no visible changes in thickness. (b) Retinal layer thickness analysis of the whole retinal, the inner plexiform layer (IPL), inner
nuclear layer (INL), and outer nuclear layer (ONL). A significant difference was determined between control and WT retinas (p < 0.01) in all layers
measured except for the ONL. This difference was not observed in C1qa+/− and C1qa−/− retinas. Further, a significant rescue of retinal thickness
could be seen between WT, C1qa+/−, and C1qa−/− animals in the whole retina (p < 0.01) and the INL (p < 0.01), and the IPL (p < 0.05) in the C1qa−/−
mice. Mean ± SEM, n = 7 per group. **p < 0.01, ***p < 0.001 compared to control and #p < 0.05, ##p < 0.01, ###p < 0.001 compared to WT–I/R
determined by One-way ANOVA followed by Holm-Sidak post test. Scale bars = 50μm
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contralateral uninjured retinas (450 ± 11 cells per mm).
However, no statistical differences were determined
between control retinas and those from C1qa+/− and
C1qa−/− mice (401 ± 31 and 394 ± 24 cells per mm, re-
spectively) (Fig. 6b). Since H&E staining is unable to dif-
ferentiate between RGCs and displaced amacrine cells,
the RGC-specific marker RNA-binding protein with
multiple splicing (Rbpms) was used for a more accurate
characterization (Fig. 6c). Again, there was a significant
difference (p < 0.01) identified between control (215 ± 8
cell per mm) and ischemic retinas (151 ± 8 cells per mm)
of WT mice. This difference was ablated in C1qa+/−
ischemic eyes (172 ± 15 cell per mm), and further a signifi-
cant difference was seen when ischemic eyes of WT mice
were compared with those of C1qa−/− animals (198 ± 16
cells per mm, p < 0.01) compared to WT (Fig. 6d). There
were no differences in RGC counts in contralateral unin-
jured and naïve retinas of WT and C1qa-deficient strains
(Additional file 1: Figure S1B and C). All counts were per-
formed in a masked manner.
Retinal functional deficits are delayed in absence of C1qa
Along with our characterization of morphological defi-
cits, we also used scotopic flash ERG to assess changes
Fig. 6 C1qa-deficiency mitigates loss of RGCs using two independent assays of cell counts 28 days following retinal I/R. (a) H&E stained and
(c) Rbpms-immunolabeled retinal cross sections used to assess RGC loss between uninjured controls and three C1qa genetic backgrounds receiving
ischemic injury. (b) Quantification of nuclei counted in the GCL determined there was a significant loss of cells (p < 0.01) in WT retinas but not in the
C1qa-deficient retinas compared to control. (d) Counts of Rbpms+ RGCs displayed a statistically significant loss (p < 0.01) in ischemic eyes of WT mice
compared to controls. No statistical differences were determined in ischemic retinas of C1qa+/− or C1qa−/− animals. However, a statistical difference
(p < 0.01) was measured when C1qa−/− retinas were compared to WT. Mean ± SEM, n = 7 per group. **p < 0.01 compared to control and ##p < 0.01
compared to WT – I/R determined by One-way ANOVA followed by Holm-Sidak post test. Scale bars = 50 μm
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in retinal function in our three genetic backgrounds.
ERG waveforms can be subdivided into multiple compo-
nents including the a-wave, or photoreceptor response,
and the b-wave, comprising the response from bipolar
and Müller cells. The b-wave is measured from the
trough of the wave to its peak. Due to changes only ob-
served in the inner retina resulting from retinal I/R, we
quantified b-wave amplitudes. Representative traces
display differences in ERG b-wave amplitudes between
ischemic and control eyes in WT mice (Fig. 7a). An in-
tensity of 3000mcd.s/m2 was chosen for quantification.
We observed a significant loss in b-wave amplitudes in
all animals 7 days following retinal I/R (p < 0.05-0.01).
While b-wave measurements remained statistically dif-
ferent in WT and C1qa+/− mice (p < 0.01) throughout
our study compared to uninjured eyes, a functional res-
cue was seen in our complete knockouts. C1qa−/− mice
were observed not only to have significantly greater
(p < 0.05) b-wave readings at day 14 compared to WT
(464.3 ± 29.3 μV and 324.5 ± 27.3 μV, respectively), but
also there was no statistical difference in comparison to
control eyes. This rescue appeared to be temporary, and
Fig. 7 C1q-deficiency delays loss of visual function due to retinal I/R. (a) Representative ERG traces observed in WT mice comparing waveforms
from ischemic and uninjured eyes across a series of flash intensities tested 28 days post injury. (b) Comparison of b-wave amplitudes over a
28 day time course at an intensity of 3000 mcd.s/m2. A statistically significant loss of b-wave response was observed in WT (p < 0.01) and C1qa+/-
(p < 0.05) ischemic eyes compared to uninjured controls at all time points. However, following initial b-wave suppression, C1qa-/- ischemic eyes
displayed a significant rescue (p < 0.05) on day 14. This rescue was transient as a slight decline was observed over the remaining two time points;
by the end no statistical differences were observed between any animals receiving ischemic injury. Mean ± SEM, n = 8 per group. *p < 0.05
**p < 0.01 ***p < 0.001 compared to control #p < 0.05 comared to WT–I/R determined by One-way ANOVA followed by Holm-Sidak post test
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by the end of our time course on day 28, no discernable
differences were observed in any animals receiving I/R in-
jury (Fig. 7b).
C1q-deficiency modulates glial response in the visual axis
after injury
Our studies conducted using WT mice established the
extent of reactive gliosis observed through the visual axis
over a 28 day time course following retinal I/R injury
(Figs. 3 and 4). Given our findings of protection ob-
served in the retina, we hypothesized C1q may be re-
sponsible for the activation and density increases
observed in glial cells. The same methodology was used
to perform density analysis in both the retina and SC in
C1qa-deficient mice. Initially, significant differences
were observed as early as day 7 post injury, and max-
imum density was measured on day 28. Therefore, we
chose these two key time points for our assessment of
glial density in the absence of C1q.
In the retina, unlike the changes observed in WT ani-
mals, no statistical differences in microglial density were
observed between ischemic and contralateral uninjured
retinas in either C1qa+/− or C1qa−/− mice at 7 and
28 days post injury (Fig. 8a). In addition, injured retinas
from C1qa-deficient mice displayed significantly de-
creased (p < 0.001) microglial density when compared
with WT injured retinas at early and late time points.
Likewise for SC microglia, no differences were observed
between hemispheres at day 7 and no significant in-
creases in density were measured between days 7 and 28
in either of our C1qa-deficient mice, as was previously
seen in WT mice (Fig. 8c). However, a different trend
was observed in astrocyte activity and density. Although
no differences were observed on day 7 in both the retina
Fig. 8 C1qa-deficiency modulates the reactive microglial but not astrocyte response in the retina and SC. a, b Bar graphs display density of Iba1+
microglia (a) or GFAP+ (b) cells in the retina at both 7 and 28 days post injury. No statistical changes between uninjured or injured C1qa+/− or C1qa−/−
mice were observed in microglia density at any time point measured; however, there was a statistically significant decrease compared with WT retinal
microglia (p < 0.001). On day 28 there was significant difference in GFAP+ cell density (p < 0.05) between ischemic and uninjured retinas of C1qa+/−
and C1qa−/− mice. c, d Bar graphs demonstrating glial cell density in the SC of C1qa-deficient mice. (c) Microglial density was unchanged in both the
ischemic-receiving and uninjured ipsilateral hemisphere at both 7 and 28 days, and C1qa−/− displayed significant decrease compared to peak microglial
density at day 28 (p < 0.05). (d) No differences were determined between hemispheres on day 7 or 28 in astrocyte density, but there was a significant
increase in density on day 28 when compared to day 7 in C1qa+/− (p < 0.01) and C1qa−/− (p < 0.05) mice. No statistical differences were measured
when C1qa-deficicient were compared to peak WT astrogliosis density. Mean ± SEM, n = 6 per group. *p < 0.05 **p < 0.01 compared to uninjured
control determined by student’s paired t-test. +p < 0.05 ++p < 0.01 compared across time points within a group determined by student’s t-test.
#p < 0.05, ###p < 0.001 compared to glial cell density of I/R injured retinas of WT mice, determined by One-way ANOVA followed by Holm-Sidak
post test
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and SC of C1qa-deficient animals, by the end of our
time course, significant changes in density were deter-
mined. Retinas of C1qa+/− and C1qa−/− mice receiving I/
R injury displayed statistically significant (p < 0.05-0.01)
increases in GFAP+ cell density (3.02 ± 0.34 and 3.05 ±
0.62 %, respectively) compared to uninjured retinas
(Fig. 8b). Similar to our results observed in the SC of
WT mice, no difference could be determined between
ipsilateral and contralateral hemispheres by day 28, and
there was a statistically significant increase in astrocyte
density compared to day 7 (p < 0.05- 0.01, Fig. 8d). In
both the retina and the SC no differences were deter-
mined when astrocyte density in C1qa+/− mice were
compared to C1qa−/− mice. Although the density of as-
trocytes was reduced when astrogliosis of C1qa-deficient
mice was compared to WT, no statistical differences
were observed. Taken all together, our data indicate re-
active gliosis was observed in both astrocytes and micro-
glia in the visual axis of WT animals, but C1qa-deficient
mice had an ablated microglial response. However, while
significant changes were observed in astrocyte density
following injury, this response also was dampened prior
to onset of pathology in comparison to that measured in
WT mice.
Discussion
Our studies have demonstrated a significant temporal
increase in C1q expression that is accompanied by an in-
crease in reactive microglial and astrocytic retinal cell
density following retinal I/R injury. Further, this re-
sponse is mirrored at RGC termination sites in the visual
system through increased C1q expression observed in
the SC. These findings agree with previous reports indi-
cating the involvement of both the complement system
and glial response to ischemic events not only in the
retina, but also areas of the brain affected by I/R Injury
[4, 12, 28, 29]. The absence of C1q provided retinal neu-
roprotection through rescue against I/R-induced retinal
thinning and neuronal loss. It should be noted that while
C1qa+/− mice do have measureable levels of C1q, follow-
ing ischemic injury, these levels were significantly re-
duced in comparison to WT retina and SC (data not
shown). Though present, this dramatic reduction likely
explains the partially protective phenotype observed in
these mice. Additionally, attenuation of the activated
microglial response in the retina and SC was observed in
C1qa-deficient animals. To our knowledge, this is the
first report to identify a time-dependent neuroinflamma-
tory response in the visual system following retinal is-
chemia, and to establish C1q as a primary mediator of
damage.
Given the wide variety of animal models of ischemic in-
jury (e.g. global, cardiac, cerebral, or retinal), several
methods for neuroprotection have met with mixed results
[30]. The retina provides a unique target for testing of
neuroprotective compounds as investigators have the op-
tion of local [31–33] or systemic [34–36] delivery of thera-
peutic compounds or biologics. We have demonstrated
significant protection against both functional and mor-
phological deficits in the retina and SC subjected to I/R
injury using the JNK inhibitor SP600125 (Kim et al., sub-
mitted for publication). Time dependent gene profiling
following retinal ischemia identifies several members of
the complement family to be among the most significant
changes as early as 7 days post injury [3, 37]. Previous
studies identifying protection of RGCs in a C3-deficient
mouse following retinal I/R demonstrated a delayed loss
of cells after 3 weeks; however, no difference in axonal
damage was seen compared with WT mice [3]. While our
endpoints differed from Kuehn et al., we were able to
show a significant rescue of RGCs and cells in the GCL.
While there exists sufficient evidence of activation of the
downstream complement cascade including C3 following
retinal ischemia, our results suggest C1q may be acting in
a cascade-independent role.
Activation of the complement system in the CNS dur-
ing times of injury and pathogenesis has been well docu-
mented [38, 39]. Increased expression of C1q has been
specifically observed to colocalize with hallmark patho-
logical changes observed in several neurodegenerative
diseases including Alzheimer’s disease (AD), Parkinson’s
disease (PD), and glaucoma [20, 40]. Furthermore, C1q
is known to directly bind to the membrane of neurons,
which have a poor capacity to regulate activation of
downstream complement cascade factors [41]. Our stud-
ies demonstrate significant upregulation of C1q at both
local and distal sites in the visual system following I/R
injury. As such, C1q has been identified as a potential
prime therapeutic target. Although not indicated for
treatment of chronic neurodegenerative disease, previous
strategies to modulate C1q have targeted C1r/C1s,
which is necessary with C1q to form the C1 complex,
using recombinant C1-INH as well as soluble CR1 [42].
In animal models of brain ischemia, administration of
C1-INH was observed to reduce infarct volume and
neurological deficits [28, 43]. Similar to our findings of
cell rescue and retinal morphology preservation, deletion
of C1q has been identified as a protective mechanism in
various other disease models. Recent in vitro data sug-
gested C1q promoted neurite progression by modulating
expression of genes necessary for outgrowth [44]. These
findings were later supported, and extended in vivo,
demonstrating axon regeneration and improved guid-
ance following spinal cord injury [45]. In both studies
however, downstream C3 and C5 had non-growth pro-
moting effects, suggesting distinct mechanistic roles for
different complement components. AD mice deficient
for C1q (APPQ−/−) significantly preserved functional
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neurons and increased dendritic staining in the hippo-
campus compared to Aβ pathological (APP) mice [46].
Accumulation of C1q during normal brain aging has
been implicated in cognitive decline; age-matched C1qa-
deficient mice were observed to perform significantly
better in a series of learning and memory behavioral
tests compared to WT mice [24]. Further, in the DBA/
2 J spontaneous glaucoma model, C1qa was identified to
be differentially expressed in the retina and ONH pre-
ceding phenotypic glaucomatous damage. Deletion of
C1qa significantly delayed RGC axonal damage [21, 22].
In our current study, we identified for the first time a
temporal response pattern for microglia and astrocyte
activation in the retina and SC after retinal I/R injury.
Furthermore, we demonstrated the significant increase
in microglial activation and cell density resulted from ac-
cumulation of C1q in the injured tissue. In the CNS, as-
trocytes, microglia, and neurons have been identified as
the primary producers of complement proteins [40, 47].
Our data support previous reports that disturbances to
the retina from injury and inflammation results in a
dynamic response of microglia, known to phagocytose
dying neurons [48–50]. Evidence suggests the increased
cell density may result from infiltrating microglia through
compromised blood-retinal barriers [51]; however, our
methodology was unable to differentiate resident and mi-
gratory microglia. Further studies utilizing fluorescently-
labeled transplanted cells will be needed to identify
whether our observed changes were due to infiltration,
proliferation, or a combination of both. Given the implica-
tion of chronic reactive microglia in neurodegenerative
disease as well as recently discovered developmental roles
[52, 53], several approaches have been made to abate
microglial activation. Neuroprotective treatment strategies
such as minocycline, irradiation, and TSPO have shown
significant suppression of microglial activation and prolif-
eration, while other methods such as modulation of
fractalkine receptor CX3CR1 have led to mixed results
[29, 48, 54–57]. These studies, along with our current
work, demonstrate the therapeutic potential of targeting
microglia in several animal models of neurodegeneration.
Furthermore, early clinical trials using oral minocycline
resulted in moderately improved visual acuity and reduc-
tion in vascular permeability in patients with diabetic
macular edema [58].
Despite our C1q-dependent modulation of activated
microglia and observed morphological protection in the
retina, we were unable to totally rescue I/R induced loss
of retinal function as assessed through scotopic ERG.
Coinciding with this finding, mice deficient in C1qa dis-
played increased levels of GFAP similar to WT animals
following retinal I/R. This supports previous results that
microglia are the primary synthesizers of complement
proteins, specifically C1q, leading to pathogenesis from
prolonged inflammatory responses [7, 56]. This suggests
following ischemic episodes in the retina, prolonged
astrocyte and Müller cell activation is stimulated by pro-
inflammatory factors different from microglia. Reactive
astrogliosis is known to be triggered by cytokines such
as TNFα, CNTF, IL-1β, and IL-6 [59]. Further, these
macroglial cells facilitate a certain degree of neurodegen-
eration independent from microglia, which may explain
our findings of visual deficits, as well as the second wave
of C1q expression observed in the SC on day 28. Similar
to microglia, astrocytes posses the machinery for synap-
tic engulfment; however, this appears to be a C1q-
independent process [60]. GFAP represents an essential
intermediate filament of reactive astrocytes necessary for
the many astroglial functions following injury [61]. Gen-
etic deletion of GFAP has provided mixed results of pro-
tection and exacerbation that appear to be dependent on
the nature of the injury [62–64]. Astrocytes, both neigh-
boring and tissue-specific, have been identified as a
highly heterogenous population in their gene expression
patterns, morphology, and proliferative responses to in-
jury, which are further complicated by their proximity
to the trauma [15]. Therefore, it is likely that retinal
astrocytes would react much differently to retinal I/R
injury compared to astrocytes in the SC. Therefore, we
find it unsurprising that elimination of C1q had no sig-
nificant effect on controlling this gliotic response in
the SC. Combinatorial therapies have had recent suc-
cess in improving pathological endpoints in models of
injury and disease [65]; therefore, targeting multiple
proinflammatory proteins may further suppress the
glial response to I/R injury, thereby providing enhanced
neuroprotection.
Conclusions
In summary, we have identified the temporal expression
patterns of C1q and the subsequent glial response to ret-
inal I/R injury to neurons in both the retina and SC.
Further, we demonstrate that retinal I/R induced neuro-
degeneration requires C1q expression, and that genetic
ablation of C1q completely inhibited the reactive micro-
glial response leading to preservation of retinal morph-
ology and significant protection of RGCs compared with
WT mice. However, retinal astrocyte and Müller cell ac-
tivation persisted likely causing the transient functional
retinal protection observed. Our results are the first to
identify a relationship between C1q and microglia fol-
lowing retinal injury, which we hypothesize to be dir-
ectly related to their roles in synaptic maturation in the
developing visual system [53]. Greater understanding of
the similarities between developmental and neurodegen-
erative signaling represents exciting new avenues for
therapeutic intervention and enhanced neuroprotection
of the visual axis.
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Methods
Animals
Male and female transgenic mice for C1qa (B6.129P2-
C1qa < tmlmjw>/Sj) that were backcrossed 10 genera-
tions onto a pure C57BL/6 J background and (hereafter
referred to as either C1qa+/− or C1qa−/−), were gener-
ously provided from the Simon John laboratory (Jackson
Laboratory; Bar Harbor, ME). Female C57BL/6 J (Jackson
Laboratory) and male and female C1qa mice (3–4 months
of age) were used for transient retinal I/R studies. Animals
were maintained in 12-h:12-h/light:dark cycle. All studies
and animal care were performed as approved by the Insti-
tutional Animal Care and Use Committee at the Univer-
sity of North Texas Health Science Center and followed
the Association for Research in Vision and Ophthalmol-
ogy (ARVO) Statement for the Use of Animals in Oph-
thalmic and Vision Research.
Retinal I/R
Retinal I/R was induced as described previously [25].
Briefly, mice were anesthetized with a ketamine/xyla-
zine/acepromazine cocktail (100/10/3 mg/kg), and the
left eyes were dilated (2.5 % Phenylephrine HCl; Paragon
BioTeck, Inc.) followed by cannulation of the anterior
chamber with a 30-gauge needle connected to a reser-
voir containing sterile PBS. The reservoir was elevated
to generate an intraocular pressure of 120 mmHg for
1 h to induce retinal ischemia. Afterwards, the cannula
was removed and blood was allowed to naturally reper-
fuse the retina. Body temperature was maintained on a
digitally controlled heating pad for the duration of the
procedure and recovery.
Immunofluorescence of the retina and SC
Following euthanasia of the mice, ischemic and contra-
lateral control eyes were gently removed and placed in
4 % paraformaldehyde (PFA) for 4 h followed by a 20 %
sucrose solution overnight. Whole brains were delicately
excised and fixed in 4 % PFA for 6–8 h, after which a
3 mm region was cut to include the superior colliculus
(SC) using a mouse brain block. The SC-containing
brain section was also embedded in a 20 % sucrose solu-
tion overnight. Eyes and brains were placed in Tissue-
Tek OCT compound (Sakura Finetek USA, Torrance,
CA) and frozen over dry ice before being stored at −80 °C.
Eyes and brains were frozen sectioned at 12 μm and
placed on Superfrost Plus slides (VWR, Radnor PA). Slides
were triple washed in PBS, blocked and permeabilized for
1 h in blocking buffer (PBS with 10 % fetal bovine serum
and 0.15 % Triton X-100) before incubation with primary
antibodies overnight at 4 °C. For retinal sections anti-C1q
(A201, 1:1000) from Quidel (San Diego, CA) was used;
however excessive non-specific labeling was observed
with this antibody in SC sections, therefore anti-C1q
(ab182451, 1:200) from Abcam (Cambridge, MA) devel-
oped by Stephan and colleagues was used [24]. For glial
cell analysis, antibodies to Iba1 (019-19741, 1:500) from
Wako Chemicals (Richmond, VA) and GFAP (ab7260,
1:300) from Abcam were used. RGC counts were per-
formed using the specific marker Rbpms (GTX118619;
1:200) from GeneTex (Irvine, CA). Tissues were incubated
in secondary antibodies conjugated with Alexafluor 488
and Alexaflour 592 (1:250; Invitrogen/Molecular Probes,
Carlsbad, CA) for 1 h at room temperature. Slides were
mounted with cover slips using ProlongGold anti-fade re-
agent with DAPI (Molecular Probes, Life Technologies,
Grand Island, NY). Images were taken using a Nikon
Eclipse Ti inverted microscope (Nikon; Melville, NY) and
CRi Nuance FX multispectral imaging system (Caliper Life
Sciences; Hopkinton, MA). Autofluorescence was sub-
tracted using Nuance 3.0 software (Caliper Life Sciences).
Cell density analysis
Density of astrocytes, Müller cells and microglia in the
retina and SC was calculated using thresholding analysis
in ImageJ (NIH; Bethesda, MD). Briefly, images were
separated by color channel into an RGB stack, after
which a region of interest (ROI) was drawn around the
entire tissue. A threshold was set to positively select only
Iba1+ or GFAP+ cells, and this threshold was maintained
for all images analyzed. Measurements were limited to
this threshold and the percent area occupied of the sec-
tion was determined. A minimum of three images per
section and three slides spanning the depth of the tissue
were analyzed and averaged per animal. A similar meth-
odology was used to assess fluorescence intensity of C1q
in retina and SC sections.
Histological assessment of the retina
Whole globes were immersion fixed in 4 % PFA over-
night at 4 °C, followed by paraffin processing. Eyes were
sectioned at 5 μm and stained with hematoxylin and
eosin (H&E). Entire retinas were imaged, ora serrata to
ora serrata through the optic nerve head, and thickness
was measured using calibrated calipers in ImageJ from
the nerve fiber layer (NFL) through the outer nuclear
layer (ONL) at two peripheral and two central locations
of the retina. Three slides were selected per retina and
the four cross sectional measurements from each retina
were averaged together. Nuclei in the H&E ganglion cell
layer (GCL), including RGCs and displaced amacrine
cells, were counted from each retina and averaged.
Scotopic flash electroretinography (ERG)
All animals were dark adapted overnight; mice were anes-
thetized with isoflurane and connected to the HMsERG
system (Ocuscience; Rolla, MO). Body temperature was
maintained at 37 °C. A ground electrode was placed
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subcutaneously by the tail and reference electrodes
inserted under each eye. Silver-thread electrodes were
placed across the apex of the cornea and held in place
with a Gonak (Akorn; Lake Forest, IL) coated contact lens.
Eyes were exposed to a series of light flashes at increasing
intensities (0.1, 0.3, 1, 3, 10, and 25 cd.s/m2). Amplitudes
and implicit times of waveforms were measured and
analyzed.
Statistics
Statistical analysis was performed using SigmaPlot 12
(Systat; San Jose, CA). Student’s paired t-test was used to
compare experimental groups within animals, ischemic
versus contralateral control. One-way ANOVA was used
to compare among three or more groups, such as com-
paring between time points for experimental groups.
Holm-Sidak post hoc analysis was used for multiple com-
parisons. All data are expressed as mean ± standard error
mean (SEM), and p-values less 0.05 were considered sta-
tistically significant.
Additional file
Additional file 1: Figure S1. C1qa-deficiency does not affect retinal
morphology. Naïve retinas from C1qa+/− and C1qa−/− were compared
to those of WT mice in all neuroprotective assays. (A) No statistical
differences were observed between all three genotypes in total retinal
thickness. Likewise, when total nuclei in the GCL (B) and Rbpms + (C)
cells in the retina were counted, no differences were determined.
Therefore, quantifications indicating preservation of retinal thickness and
neuron counts are not due to developmental differences within the
retina between transgenic and WT mice. Mean ± SEM, n = 5 per group.
(PDF 140 kb)
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